Q-omics provides the consensus-scored SEMA5B profile across patient tissues and cancer cell-line models. SEMA5B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SEMA5B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SEMA5B RNA expression shows 17,537 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where SEMA5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA5B survival associations across molecular data types. SEMA5B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA5B RNA expression–survival associations across cancer types. High SEMA5B expression shows unfavorable associations in UVM, LIHC, THCA, CESC and STAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SEMA5B RNA expression.
This table summarizes SEMA5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SEMA5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA5B shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, COAD, LIHC and STAD. The KIRC box plot shows higher SEMA5B RNA expression in tumor versus normal tissue (log2 FC = +4.018, t-test p < 0.001).
This table shows molecular features associated with SEMA5B in patient tissues and cancer cell lines. In patient samples, SEMA5B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
